Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication

por Tiong, Ing S., Loo, Sun
Publicado 2023

FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue

por Loo, Sun, Wei, Andrew H.
Publicado 2021

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

por Loo, Sun, Dillon, Richard, Ivey, Adam, Anstee, Natasha S., Othman, Jad, Tiong, Ing Soo, Potter, Nicola, Jovanovic, Jelena, Runglall, Manohursingh, Chong, Chyn Chua, Bajel, Ashish, Ritchie, David, Gray, Kelli, Yeoh, Zhi Han, McBean, Michelle, Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Russell, Nigel H., Wei, Andrew H.
Publicado 2022